Report: Sanofi has billion-dollar dengue opportunity in India

Sanofi Pasteur's India head Stephan Barth

Analysts have said Sanofi's ($SNY) dengue vaccine, once approved, could rake in €1 billion, or $1.31 billion, a year. But as the Business Standard reports, India alone is a billion-dollar opportunity. According to a report from Brandeis University, the number of cases in the country is almost 300 times higher than government figures. "Over recent months, we have seen a worrying increase in cases, putting a huge strain on health care systems," Stephan Barth, Sanofi Pasteur's India head, told the paper, noting that India is part of the company's global development strategy for the dengue vaccine. Story | Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.